Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer: A systematic review of the literature

Medical Oncology

Volumn 25, Issue 3, 2008, Pages 323-330

  Noel, J Kay ^a   Crean, Sheila ^a   Claflin, Janet E ^a   Ranganathan, Gayatri ^a   Linz, Heather ^a   Lahn, Michael ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse effects; Clinical trials; Design; Drug; Drug modeling; Humans; Neoplasms; Safety

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SORAFENIB; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANEMIA; ANOREXIA; ASTHENIA; ATAXIA; BRADYCARDIA; CANCER PATIENT; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INFECTION; LETHARGY; LEUKOPENIA; LIVER FUNCTION; LYMPHOCYTOPENIA; MONOTHERAPY; MOOD CHANGE; MULTIPLE MYELOMA; NAUSEA; NEOPLASM; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN ALLERGY; SKIN TINGLING; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREMOR; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VERTIGO; VOMITING; WEAKNESS; XEROSTOMIA; DRUG ANTAGONISM;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; HUMANS; NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; THALIDOMIDE;

EID: 58149262009     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9039-1     Document Type: Review

References (41)

1. DW Hommes MP Peppelenbosch SJH. van Deventer 2003 Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets Gut 52 144 51
2. LC. Plantanias 2003 Map kinase signaling pathways and hematologic malignancies Blood 101 4667 79
3. DV Bulavin AJ Fornace Jr. 2004 P38 MAP kinase's emerging role as a tumor suppressor Adv Cancer Res 92 95 118
4. JM Olson AR. Hallahan 2004 P38 MAP kinase: a convergence point in cancer therapy Trends Mol Med 10 125 9
5. RM. Schultz 2003 Potential of p38 MAP kinase inhibitors in the treatment of cancer Prog Drug Res 60 59 92
6. T Hideshima 2003 Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu Blood 101 703 5
7. EA Eisenhauer PJ O'Dwyer M Christian JS. Humphrey 2005 Phase I clinical trial design in cancer drug development J Clin Oncol 18 684 92
8. E Horstmann MS McCabe L Grochow 2005 Risks and benefits of Phase I oncology trials, 1991 through 2002 N Engl J Med 352 895 904
9. TG Roberts 2004 Trends in the risks and benefits to patients with cancer participating in Phase I clinical trials JAMA 292 2130 40
10. Alderson P, Green S, Higgins JPT, editors. Cochrane collaboration handbook 4.2.1 [updated December 2003]. Chichester, UK: John Wiley & Sons, 2004
11. [The Cochrane Library, Issue 1, 2004].
12. DJ Cook CD Mulrow RG. Haynes 1997 Systematic reviews: synthesis of best evidence for clinical decisions Ann Intern Med 126 376 80
13. Baz R, et al. Aspirin decreases the throbotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM). Proc ASH 2004, abstract 2397.
14. SJ Bowcock SM Rassam SM Ward JT Turnder M. Laffan 2002 Thromboembolism in patients on thalidomide for myeloma Hematology 7 51 3
15. A Corso 2004 Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone Ann Hematol 83 588 91
16. MC Minnema R Fijnheer PG de Groot HM. Lokhorst 2003 Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment J Thromb Haemost 1 445 9
17. Moehler TM, et al. Low incidence of deep vein thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. Proc ASH 2002, abstract 5136.
18. M Streetly 2005 Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis Eur J Haematol 74 293 6
19. M Zangari 2003 Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival Clin Lymphoma 4 32 5
20. M Zangari 2004 Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation Br J Haematol 126 715 21
21. Caravita T, et al. Thalidomide induced neuropathy in patients treated for multiple myeloma. Proc ASH 2002, abstract 5105.
22. S Laaksonen K Remes K Kosela LM Voipio-Pulkki B. Falck 2005 Thalidomide therapy and polyneuropathy in myeloma patients Electromyogr Clin Neurophysiol 45 75 86
23. P Tosi 2005 Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma Eur J Haematol 74 212 6
24. Y Hattori T Kakimoto S Okamoto N Sato Y. Ideka 2004 Thalidomide-induced severe neutropenia during treatment of multiple myeloma Int J Haematol 79 283 88
25. VC Hall RA El-Azhary S Bouwhuis SV. Rajkumar 2003 Dermatologic side effects of thalidomide in patients with multiple myeloma J Am Acad Dermatol 48 548 52
26. Badros A, et al. Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. Proc ASH 2000, abstract 4973.
27. Pavlick AC, Gershenhorn B. Lymphopenia and herpes zoster infections in metastatic melanoma patients treated with temozolomide and thalidomide. Proc ASCO 2003, abstract 2866.
28. C Dominguez DA Powers N. Tamayo 2005 p38 MAP kinase inhibitors: Many are made, but few are chosen Curr Opin Drug Discov Deve 8 421 30
29. JB Bartlett K Dredge AG. Dalgleish 2004 The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 314 22
30. RJ D'Amato MD Loughnan E Flunn J. Folkman 1994 Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 4082 5
31. S Singhal 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565 71
32. MA. Hussein 2005 Thalidomide: present and future in multiple myeloma Expert Rev Anticancer Ther 5 25 31
33. D. Weber 2003 Thalidomide and its derivatives: New promise for multiple myeloma Cancer Control 10 375 83
34. SK Teo DI Stirling JB. Zeldis 2005 Thalidomide as a novel therapeutic agent: New uses for an old product Drug Discov Today 10 107 14
35. IM Ghobrial SV. Rajkumar 2003 Management of thalidomide toxicity J Supp Oncol 1 194 205
36. JN Gordon PM. Goggin 2003 Thalidomide and its derivatives: Emerging from the wilderness Postgrad Med J 79 127 32
37. L Newman 1993 Assessment of the effectiveness of animal developmental toxicity testing for human safety Reprod Toxicol 7 359 90
38. J Zeldis 1999 S.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomide Clin Ther 21 319 30
39. A List 2005 Effiacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 549 57
40. SA Schey 2004 Phase I study of an immunomodulatory thalidomide analog, CC-4017, in relapsed or refractory multiple myeloma J Clin Oncol 22 3269 76
41. SM Wilhelm 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 109